FONAR (FONR) Competitors

FONAR (NASDAQ:FONR) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.

Is FONR or NPCE more profitable?

FONAR has a net margin of 9.41% compared to NeuroPace's net margin of -36.74%. FONAR's return on equity of 6.10% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FONAR	9.41%	6.10%	4.58%
NeuroPace	-36.74%	-205.41%	-28.29%

Do analysts recommend FONR or NPCE?

NeuroPace has a consensus price target of $15.33, suggesting a potential upside of 4.38%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts plainly believe NeuroPace is more favorable than FONAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FONAR	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NeuroPace	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Which has more volatility and risk, FONR or NPCE?

FONAR has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.

Does the media prefer FONR or NPCE?

In the previous week, NeuroPace had 10 more articles in the media than FONAR. MarketBeat recorded 12 mentions for NeuroPace and 2 mentions for FONAR. NeuroPace's average media sentiment score of 0.63 beat FONAR's score of 0.47 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FONAR	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroPace	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of FONR or NPCE?

50.6% of FONAR shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 2.2% of FONAR shares are owned by insiders. Comparatively, 22.2% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer FONR or NPCE?

FONAR received 151 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 74.69% of users gave FONAR an outperform vote while only 59.18% of users gave NeuroPace an outperform vote.

Company	Underperform	Outperform
FONAR	Outperform Votes 180 74.69%	Underperform Votes 61 25.31%
NeuroPace	Outperform Votes 29 59.18%	Underperform Votes 20 40.82%

Which has higher earnings and valuation, FONR or NPCE?

FONAR has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than FONAR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FONAR	$102.88M	0.98	$10.57M	$1.40	11.43
NeuroPace	$65.42M	6.70	-$32.96M	-$1.00	-14.69

Summary

FONAR and NeuroPace tied by winning 9 of the 18 factors compared between the two stocks.